PolTREG’s regulatory T cell therapy shows promise in type-1 diabetes 25-Jun-2024 By Clara Rodriguez Fernandez Results from a phase 1/2 clinical trial revealed that PolTREG’s regulatory T cell (Treg) therapy, PTG-007, was able to restore insulin secretion in children with type-1 diabetes.